Mortality rates in patients with Alzheimer's disease treated with atypical neuroleptic drugs;Mortalidad en pacientes con enfermedad de Alzheimer tratados con neurolépticos atípicos

Revista de Neurologia

Volumn 46, Issue 3, 2008, Pages 129-134

  Vilalta Franch, Joan ^a   Lopez Pousa S ^a   Garre Olmo, J ^a   Turon Estrada A ^a   Pericot Nierga, I ^a  

^a HOSPITAL SANTA CATERINA   (Spain)

Author keywords

Alzheimer's disease; Anticholinesterases; Antipsychotics; Metabolic syndrome; Mortality; Olanzapine; Physiopathogenesis; Risperidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; MEMANTINE; OLANZAPINE; RISPERIDONE;

ADULT; AGE DISTRIBUTION; ALZHEIMER DISEASE; ARTICLE; CONDUCT DISORDER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MINI MENTAL STATE EXAMINATION; MORTALITY; RATING SCALE; SEX RATIO; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 40849083864     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4603.2007382     Document Type: Article

References (55)

1. Kuehn BM. FDA warns antipsychotics drugs may be risk for elderly. JAMA 2005; 293: 2462.
2. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 253: 2335-41.
3. Nasrallah HA, White T, Nasrallah AT. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol. Am J Geriatr Psychiatry 2004; 12: 437-9.
4. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang OS. Risk of death associated with use of conventional versus atypical antipsychotics drugs among elderly patients. CMAJ 2007; 176: 627-32.
5. Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113-5.
6. Craig J. Increased risk of cerebrovascular adverse events and death in elderly demented patients treated with atypical antipsychotics: what's a clinician to do? J Clin Psychiatry 2005; 66: 1071.
7. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. Meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-43.
8. Haupt M, Cruz-Jentoft A, Jeste D. Mortality in elderly dementia patients treated with risperdione. J Clin Psychopharm 2006; 26: 566-570.
9. Kryzhanovskaya LA, Jeste DV, Young CA, Polzer JP, Roddy TE, Jansen JF, et al. A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia. J Clin Psychiatry 2006; 67: 933-45.
10. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329: 75.
11. Deberdt WG, Dysken MW, Rappaport SA, Feldman PD, Young VCA, Hay DP, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry 2005; 13: 722-30.
12. Sink HM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. A review of the evidence. JAMA 2005; 293: 596-608.
13. Rabins PV, Lyketsos CG. Antipsychotic drugs in dementia. What should be made of the risks? JAMA 2005; 294: 1963-5.
14. Folstein MF, Folstein SE, McHugh PR. Mini Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
15. Blessed G, Tomilson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797-811.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
17. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-9.
18. Linn BS, Linn MW, Gurel L. Cumulative Illness Rating Scale. J Am Geriatr Soc 1968; 16622-6.
19. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-8.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
21. Singh S, Wooltorton E. Increased mortality among elderly patients with dementia using atypical antipsychotics. CMAJ 2005; 173: 252.
22. Sijand H, Jaojoco J, Linares L, Phillips PS. Atypical antipsychotic drugs, dementia and risk of death. JAMA 2006; 295: 495.
23. Gause-Nilsson I, Gherman S, Kumar Dey D, Kennerfalk A, Steen B. Prevalence of metabolic syndrome in an elderly Swedish population. Acta Diabetol 2006; 43: 120-6.
24. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
25. Sandhofer A, Iglseder B, Paulweber B, Ebenbichler CF, Patsch JR. Comparison of different definitions of the metabolic syndrome. Eur J Clin Invest 2007; 37: 109-16.
26. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hänninen T, Soininen H, et al. Association of metabolic syndrome with Alzheimer disease. A population-based study. Neurology 2007; 67: 843-7.
27. Razay G, Vreugdenhil A, Wilcok G. The metabolic syndrome and Alzheimer disease. Arch Neurol 2007; 64: 93-6.
28. Chew GT, Gan SK, Watts GF. Revisiting the metabolic syndrome. Med J Aust 2006; 185: 445-9.
29. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotics drugs. J Clin Psychiatry 2006; 67: 575-83.
30. Sacks FM. Metabolic syndrome: epidemiology and consequences. J Clin Psychiatry 2004; 65: 3-12.
31. Micca JL, Hoffmann VP, Lipkovich I, Ahl J, Baker RW, Hardy TA. Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trials. Am J Geriatr Psychiatry 2006; 14: 62-70.
32. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-9.
33. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA 2002; 288: 2709-16.
34. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173: 309-14.
35. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119: 812-9.
36. McNeill AM, Katz R, Girman CJ, Rosamond WD, Wagenknecht LE, Barzilay JI, et al. Metabolic syndrome and cardiovascular disease in older people: the cardiovascular health study. J Am Geriatr Soc 2006; 54: 1317-24.
37. Ravaglia G, Forti P, Maioli F, Bastagli L, Chiappelli M, Montesi F, et al. Metabolic syndrome. Prevalence and prediction of mortality in elderly individuals. Diabetes Cre 2006; 29: 2471-6.
38. Alberti KGMM, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-62.
39. Després JP, Lemieu I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-7.
40. Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand 2003; 107: 85-95.
41. Al-Khatib SM, Allen LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003; 289: 2120-7.
42. Zareba W, Lin DA. Antipsychotic drugs and QT interval prolongation. Psychiatr Q 2003; 74: 291-306.
43. Mackin P, Young AH. QTc interval measurement and metabolic parameters in psychiatric patients taking typical atypical antipsychotic drugs: a preliminary study. J Clin Psychiatry 2005; 66: 1386-91.
44. Straus SMJ, Bleumink GS, Dieleman JP, Van der Lei J, 't Jong GW, Kingma JH, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004; 164: 1293-7.
45. Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population. Arch Intern Med 2004; 164: 943-8.
46. Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JRS, Caverzasi E, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry 2004; 4: 1-6.
47. Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005; 66: 5-10.
48. Vieweg WVR. New generation antipsychotic drugs and QTc interval prolongation. J Clin Psychiatry 2003; 5: 205-15.
49. Gambassi G, Lapane KL, Landi F, Sgadari A, Mor V, Bernabie R. Gender differences in the relation between comorbidity and mortality of patients with Alzheimer's disease. Systematic Assessment of Geriatric drug use via Epidemiology (SAGE) Study Group. Neurology 1999; 52: 737-43.
50. Lapane KL, Gambassi G, Landi F, Sgadari A, Mor V, Bernabei R. Gender differences in predictors of mortality in nursing home residents with AD. Neurology 2001; 56: 650-4.
51. Stump TE, Callahan CM, Hendrie HC. Cognitive impairment and mortality in older primary care patients. J Am Geriatr Soc 2001; 49: 934-40.
52. Ueki K, Shinjo H, Shimode H, Nakajima T, Morita Y. Factors associated with mortality in patients with early-onset Alzheimer's disease: a five-year longitudinal study. Int J Geriatr Psychiatry 2001; 16: 810-5.
53. Friedman JH. Atypical antipsychotics have very different adverse effect profiles and should not be lumped together. Arch Intern Med 2006; 166: 586.
54. American Diabetes Associations. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27 (Suppl 1): S5-S10.
55. Chobaninan AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al, and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high blood pressure. JAMA 2003; 289: 2560-72.